Over the past several years, GLP-1 medications have transformed the treatment of obesity and Type 2 diabetes. While many people recognize these medications for their ability to promote significant weight loss, researchers have discovered that their benefits extend far...
A Review of the Science Behind Medicare’s New Approach to Obesity Treatment and Cardiovascular Disease Prevention Beginning in July 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program, a temporary demonstration...
For many people, losing weight isn’t simply a matter of eating less and exercising more. Obesity is now recognized as a chronic medical condition influenced by genetics, hormones, metabolism, medications, stress, sleep, and lifestyle. Fortunately, advances in...
